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Abstract
It has been recently suggested that activation of 5-HT4 receptors might exert antidepressant-like eﬀects in
rats after 3 d treatment, suggesting a new strategy for developing faster-acting antidepressants. We
studied the eﬀects of 3 d and 7 d treatment with the 5-HT4 receptor partial agonist RS67333 (1.5 mg/kg.d)
in behavioural tests of chronic eﬃcacy and on neuroplastic-associated changes, such as adult hippocampal
neurogenesis, expression of CREB, BDNF, b-catenin, AKT and 5-HT4 receptor functionality. RS67333
treatment up-regulated hippocampal cell proliferation, b-catenin expression and pCREB/CREB ratio after
3 d treatment. This short-term treatment also reduced immobility time in the forced swim test (FST),
together with a partial reversion of the anhedonic-like state (sucrose consumption after chronic cortico-
sterone). Administration of RS67333 for 7 d resulted in a higher increase in the rate of hippocampal cell
proliferation, a signiﬁcant desensitization of 5-HT4 receptor-coupled adenylate cyclase activity and a more
marked increase in the expression of neuroplasticity-related proteins (BDNF, CREB, AKT) : these changes
reached the same magnitude as those observed after 3 wk administration of classical antidepressants.
Consistently, a positive behavioural response in the novelty suppressed feeding (NSF) test and a complete
reversion of the anhedonic-like state (sucrose consumption) were also observed after 7 d treatment. These
results support the antidepressant-like proﬁle of RS67333 with a shorter onset of action and suggest that
this time period of administration (3–7 d) could be a good approximation to experimentally predict the
onset of action of this promising strategy.
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Introduction
Depressive disorders are currently treated with drugs
that mainly act by increasing brain monoamine levels
(Adell et al. 2005). These drugs usually require 2–5 wk
to improve the symptoms of the disease (Nierenberg
et al. 2000). Thus, generating new drugs with a faster
eﬀect is a critical issue in order to avoid the dramatic
consequences of this illness.
Antidepressant-like properties have been recently
shown for the 5-HT4 receptor partial agonist RS67333.
This drug has been shown to be eﬀective in the forced
swim test (FST) (Lucas et al. 2007). After 3 d treat-
ment in rats, this 5-HT4 receptor agonist induced
a powerful electrophysiological desensibilization of
the 5-HT1A receptor in the dorsal raphe, as well as
an increase in hippocampal cell proliferation and
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CREB phosphorylation, in a similar manner to classi-
cal antidepressants (Lucas et al. 2007). Regarding
other behavioural tests, 3 d treatment with RS67333
resulted in a partial abolishment of the hyper-
locomotion induced by olfactory bulbectomy: the
complete reversion was observed after 14 d RS67333
treatment. Furthermore, treatment with this agonist
reached its maximal eﬃcacy in the chronic mild
stress model after 10 d administration. Therefore, it
could be of interest to perform additional tests for
indicators of antidepressant chronic response, in order
to further characterize the pharmacological proﬁle of
this drug as an antidepressant with shorter onset of
action than existing antidepressants. To this end we
chose the novelty suppressed feeding (NSF) and the
chronic corticosterone model as validated experimen-
tal paradigms to assess the chronic eﬀects of anti-
depressants (Dulawa & Hen, 2005 ; Gourley et al.
2008a, b).
Moreover, several hippocampal neuroplastic
changes, especially at the level of the dentate gyrus
(DG), occur only after chronic treatment with classi-
cal antidepressants and are associated with anti-
depressant chronic eﬃcacy (Adachi et al. 2008;
Airan et al. 2007; Keith et al. 2007). It is now well
accepted that antidepressants increase the rate of
adult hippocampal proliferation after chronic but
not acute treatment (Malberg et al. 2000; Santarelli
et al. 2003). In addition, several neuroplasticity and
proliferation related intracellular pathways appear
to be involved in the mechanism of action of anti-
depressants, especially at the hippocampal level.
They include BDNF (Bravo et al. 2009; Duman &
Monteggia, 2006), CREB (Malberg & Blendy, 2005;
Tardito et al. 2009), AKT (Mostany et al. 2008;
Soumier et al. 2009) and b-catenin (Madsen et al. 2003;
Mostany et al. 2008) pathways. Since chronic anti-
depressants have been reported to modulate 5-HT4
receptor-coupled adenylate cyclase activity (Vidal
et al. 2009, 2010), it would be of interest to analyse
whether short-term administration of 5-HT4 agonists
results in the modiﬁcation of this transductional
signal.
The aim of this work was to study the time-course
of the changes induced by short-term administration
of RS67333 (3 d and 7 d) on behavioural responses and
hippocampal neuroplasticity related to chronic anti-
depressant eﬃcacy.
Method
For a complete description of methods, see Sup-
plementary material (available online).
Animals and treatments
All experimental procedures were performed accord-
ing to Spanish legislation and the European Com-
munities Council Directive on ‘Protection of Animals
Used in Experimental and Other Scientiﬁc Purposes’
(86/609/EEC).
Male Sprague–Dawley rats weighting 270–320 g
(except in the case of adult neurogenesis assessment
that began with 350–400 g rats) were group-housed
and maintained on 12-h light/dark cycle with food
and water available ad libitum. Animals received
1.5 mg/kg.d RS67333 or vehicle subcutaneously
(osmotic minipumps) for 3 d or 7 d, depending on
the experimental process. In the case of ﬂuoxetine,
it was administered in drinking water (10 mg/kg.d)
for 7, 14 or 21 d.
Immunohistochemistry
On the last day of antidepressant treatment, animals
received BrdU (2r100 mg/kg every 12 h, i.p.) and
were perfused with 4% paraformaldehyde. BrdU
immunohistochemistry was performed in 40 mm
sections as described previously by Mostany et al.
(2008). The total number of cells with b-catenin cyto-
plasmatic accumulations in the subgranular zone of
DG and the subtypes of adult neural progenitors and
neuroblasts expressing b-catenin were quantiﬁed by
immunohistochemistry and immunoﬂuorescence co-
localization with antibodies against b-catenin, GFAP,
SOX2, BLBP and DCX. The diﬀerent cell types were
classiﬁed according to their morphology and the ex-
pression of phenotype markers. Quiescent neural
progenitors (QNPs) present a triangular soma with
processes that cross the granule cell layer and express
GFAP, SOX2 and BLBP. However, amplifying neural
progenitors (ANPs) express SOX2 and BLBP but not
GFAP and have very short processes (Encinas et al.
2006). Immature neuroblasts are positive for DCX and
their diﬀerentiated state was achieved by the length
and arborization of their processes and SOX2 ex-
pression.
Western blot
The whole hippocampus or the diﬀerent hippocampal
regions were dissected as described by Newton et al.
(2005) in order to obtain total cell lysate samples that
were processed as previously described (Mostany et al.
2008). Membranes were incubated overnight in the
following primary antibodies : anti-b-catenin, anti-
GAPDH, anti-AKT1, anti-BDNF, anti-CREB and anti-
pCREB. Secondary antibodies conjugated to horse-
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radish peroxidase were detected with the ECL
Advance kit (UK). Blot quantitations were performed
by densitometric scanning using Scion Image Software
(USA). The densitometry values were normalized
against GAPDH values.
In-situ hybridization
Cryostat sections (20 mm) were thaw-mounted onto
slides and pre-treated for in-situ hybridization.
Oligonucleotides complementary to BDNF mRNAs
(5k-GGT CTC GTA GAA ATA TTG GTT CAG TTG
GCC TTT TGA TAC CGG GAC-3k (Zetterstrom et al.
1998) were 3k-end-labelled with [35S]dATP using ter-
minal deoxynucleotide transferase and added to each
section. After incubation, they were washed and ex-
posed to ﬁlm together with 14C microscales atx20 xC
for 3 wk (Vaidya et al. 2001). The abundance of mRNA
in hippocampus was analysed and quantiﬁed using
Scion Image Software. Optical density values were
calibrated to 35S tissue equivalents using 14C micro-
scales.
Adenylate cyclase assay
Hippocampi were homogenized (1 :160, w/v) in ice-
cold membrane buﬀer (MB), and centrifuged at 500 g
for 5 min at 4 xC. The supernatant was centrifuged at
12 000 g for 5 min at 4 xC. The pellet was resuspended
(1 :160, w/v) in stimulation buﬀer (SB) (MB buﬀer
containing 10 mM ATP magnesium salt). The protein
concentration used per assay was 0.9–1 mg/ml. The in-
cubation reaction consisted of 5 ml membrane hom-
ogenate and 5 ml SB alone (basal condition) or in the
presence of diﬀerent concentrations of the 5-HT4
agonist zacopride (10x6 to 10x3 M). Measurement of
cAMP was performed using an AlphaScreen cAMP
Assay kit (PerkinElmer, USA). Protein concentration
was determined using Bio-Rad Protein Assay kit
(USA) with c-globulin as standard.
Behavioural tests
Novelty-supressed feeding (NSF). The latency of each
animal to eat a single food pellet placed in the centre of
an open-ﬁeld arena was measured (10-min session)
after 24 h food deprivation. After the test, each animal
was transferred to its home cage, and the individual
latency to feed as well as home food consumption
were measured during a 5-min session. If an animal
did not eat during the open-ﬁeld session, a latency
value of 10 min was assigned. Those animals showing
no feeding behaviour in the home cage were excluded
from data analysis.
Forced swim test (FST). Rats were placed individually
into a water-ﬁlled cylinder (25 cm diameter, 65 cm
height ; 45 cm depth ; 23–25 xC). The total immobility
time was measured during a 5-min period.
Sucrose consumption and preference after chronic
corticosterone administration. Animals were chronically
administered corticosterone in the drinking water for
20 d (Gourley & Taylor, 2009). Following treatment
with either RS67333 or ﬂuoxetine, theywere habituated
to sucrose for 2 d (5% in drinking water). Then, the
amount of total intake (sucrose and water intake in
ml), sucrose consumption (ml), and sucrose preference
(percentage of sucrose intake vs. total intake) of each
animal was measured during a 1-h period after 4,
14 and 19 hwater deprivation. See experimental design
in Fig. 1c.
Data and statistical analysis
Data are expressed as a percentage of vehicle group
values (100%) and are presented as the mean¡S.E.M.
Diﬀerences among the experimental groups were
evaluated by unpaired Student’s t test (when two
experimental groups were included) or one-way
ANOVA followed by Student–Newman–Keuls post-
hoc test when appropriate (GraphPad Prism 5.01;
USA). The level of signiﬁcance was chosen at p<0.05.
For speciﬁc analysis of data corresponding to the
diﬀerent experimental procedures see online Sup-
plementary Material.
Results
Behavioural responses related to chronic eﬃcacy
In the FST, a signiﬁcant reduction in immobility time
had been observed in animals treated for 3 d with
RS67333 (x24.7¡2.7%, p<0.01 ; Fig. 1a). This re-
sponse was still present after 7 d treatment (x40.5¡
5.6%, p<0.01 ; Fig. 1a) compared to their respective
vehicle groups. The lack of temporal parallelism be-
tween positive response in FST and the course of
clinical eﬃcacy for antidepressant drugs is well
known. Thus, we undertook another well-validated
paradigm to evaluate the antidepressant-like eﬀects
of drugs, i.e. sucrose intake in rats exposed to chronic
corticosterone. As previously reported (Gourley &
Taylor, 2009), corticosterone-treated rats showed an
anhedonic behaviour, a pathognomonic feature of
depression states, as they exhibited decreased sucrose
preference (relative sucrose intake y50%) (Fig. 1d)
compared to naive rats. The administration of
RS67333 for 3 d induced a partial reversion of that
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anhedonic-like state (relative sucrose intake y65%).
However, the complete reversion was only observed
after 7 d treatment, paralleling the eﬀect of 21 d treat-
ment with ﬂuoxetine (Fig. 1d). When analysing su-
crose consumption, there was a marked reduction in
the corticosterone group compared to naive rats
(6.7¡1.6 and 23.6¡1.5 ml, respectively, p<0.01). The
administration of ﬂuoxetine for 21 d fully reversed
that corticosterone-induced reduction in sucrose in-
take (22.3¡2.9 ml, p<0.01 vs. corticosterone rats).
Treatment with the 5-HT4 receptor agonist RS67333 for
3 d signiﬁcantly attenuated that anhedonic-like state,
although the amount of sucrose intake did not reach
the values of the naive group (15.5¡1.3 ml, p<0.05 vs.
corticosterone group and p<0.05 vs. naive group).
Interestingly, 7 d treatment with RS67333 resulted in
a complete reversion of sucrose consumption (23.0¡
0.7 ml, p<0.01 vs. corticosterone group). The amount
of total intake (total ml of sucrose solution+water
measured during a 1-h session) was signiﬁcantly re-
duced in corticosterone-treated animals compared to
naive rats (13.6¡2.5 and 25.2¡2.5 ml, respectively,
p<0.01). The total intake in the group of animals
treated with RS67333 for 3 d and 7 d, and with
ﬂuoxetine was similar to that observed in naive ani-
mals and signiﬁcantly higher than that measured in
corticosterone-treated animals (3-d RS67333 : 23.1¡
2.0 ml ; 7-d RS67333 : 28.6¡2.7 ml ; 21-d ﬂuoxetine :
26.9¡1.5 ml ; p<0.01, p<0.001, p<0.01 vs. cortico-
sterone group, respectively).
Moreover, we also assessed the chronic eﬀects of
drug treatments, in an anxiety-related test, the novelty
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Fig. 1. Behavioural eﬀects of 3-d and 7-d RS67333 treatment on (a) the forced swim test (FST) and (b) the novelty suppressed
feeding (NSF) paradigm. (c) Experimental timeline on the sucrose-preference paradigm in rats exposed to chronic corticosterone,
and (d) sucrose preference in the corticosterone model (% of sucrose intake vs. total intake). Note that 3-d RS67333 treatment
attenuates the depressive-like eﬀect, although after 7 d treatment the behavioural values are comparable to those observed
with the classical antidepressant ﬂuoxetine after its chronic administration (see online Supplementary Material). Data are
mean¡S.E.M. of 8–9 animals per group. * p<0.05 and ** p<0.01 vs. vehicle group for FST and NSF (Student’s t test). # p<0.05 vs.
vehicle group and * p<0.05 vs. corticosterone-treated group for the sucrose preference test after chronic corticosterone
administration (one-way ANOVA followed by Student–Newman–Keuls post-hoc test).
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suppressed feeding (NSF). A slight reduction in the
latency to feed was observed following 3 d treatment
with RS67333 (x16.7¡11.7%; Fig. 1b), without
reaching statistical signiﬁcance. However, a signiﬁcant
reduction had been observed following 7 d RS67333
treatment compared to the vehicle-treated counter-
parts (x29.0¡5.3%, p<0.05 ; Fig. 1b). No signiﬁcant
diﬀerences were detected in the latency to feed in the
home cage (5-min session) between animals treated for
3 d (2.1¡0.7 min) or 7 d (1.9¡0.5 min) with RS67333
and vehicle groups (1.9¡0.5 and 2.0¡0.7 min for 3-d
and 7-d vehicle groups, respectively). Further, there
were no signiﬁcant diﬀerences in home food con-
sumption (tested in a 5-min session and following the
open-ﬁeld NSF) between animals treated for 3 d
(1.7¡0.2 g) or 7 d (1.8¡0.4 g) with RS67333 and their
respective vehicle groups (3 d: 1.5¡0.2 g ; 7 d:
1.6¡0.3 g), thus discarding any eﬀect of RS67333 on
home food consumption. On the other hand, the SSRI
ﬂuoxetine, administered for 7 d in drinking water
(10 mg/kg.d), did not induce any behavioural eﬀect in
NSF test compared to the vehicle group. In contrast,
after 2 wk ﬂuoxetine treatment, a signiﬁcant reduction
in the latency of feeding in the NSF was observed (see
Supplementary Fig. S1, online) without aﬀecting
latency to feed and food consumption in the home
cage (data not shown).
Hippocampal proliferation in b-catenin+ cells
The number of BrdU+ cells in the DG was signiﬁ-
cantly increased after 3 d administration of RS67333
(119.3¡5.7%, p<0.05 ; Fig. 2a–d). Moreover, an in-
crease of similar magnitude was observed in the
number of b-catenin+ clusters in the subgranular zone
of the DG (122.6¡6.7%, p<0.05 ; Fig. 3a–d). Since
classical antidepressants (e.g. ﬂuoxetine) target ANPs
(Encinas et al. 2006), we decided to explore if RS67333
treatment was targeting b-catenin in the same type of
cells, addressing the co-localization of this protein
with neural progenitor markers.
Regarding the cellular phenotype (see Methods,
online), the majority of cells with b-catenin cytoplas-
matic accumulations were ANPs and immature
neuroblasts, with only a small portion of QNPs
(Fig. 2 i). The number of b-catenin-expressing ANPs
(b-catenin+, Sox2+, GFAP–), were increased with re-
spect to vehicle (125.7¡6.5%, p<0.05 ; Fig. 2g, j) after
3-d treatment with the 5-HT4 agonist. No diﬀerences
were observed in QNPs (b-catenin+, Sox2+, GFAP+)
positive for b-catenin (105.1¡6.0%; Fig. 2 f) as well as
in the total number of doublecortin immunopositive
neurons (107.7¡8.7%; Fig. 2e), showing that RS67333
speciﬁcally targets ANPs. Moreover, when the imma-
ture neuroblasts (b-catenin+, Sox2+, DCX+) with very
short processes expressing b-catenin were counted,
an increase was observed (120.5¡5.8%, p<0.05 ;
Fig. 2h, k). These data suggest that the b-catenin path-
way could be involved in the diﬀerentiation of ANPs
to neurons induced by RS67333.
Treatment with RS67333 for 7 d increased the
number of BrdU cells in the DG by almost 50%
(149.5¡9.8%, p<0.01 ; Fig. 2a, c, d) reaching the values
observed after treatment with typical antidepressants.
A similar increase in the total number of b-catenin+
clusters in the subgranular zone with respect to its
vehicle (143.5¡9.9%, p<0.01 ; Fig. 3a–d), was ob-
served following 7 d administration.
b-catenin is not only expressed in neural progeni-
tors, but also plays an important role in dendritic
arborization and synapse formation in hippocampal
adult neurons (Yu & Malenka, 2003). When b-catenin
expression was measured by Western blot in hippo-
campal total cell lysates, signiﬁcant higher levels of
this protein were found after a 3-d RS67333 treatment
(129.9¡8.4%, p<0.05 ; Fig. 3e), this increase being
maintained after the 7-d regimen (146.5¡4.6%,
p<0.05 ; Fig. 3e).
BDNF expression in DG
As shown in Fig. 4(a, b, e), 3-d RS67333 administration
resulted in increased BDNF mRNA expression in the
CA3 area (128.2¡5.6%, p<0.01) but not in CA1
(127.7¡8.4%) or DG (109.6¡3.8%) of the hippo-
campus. However, after the 7-d regimen no diﬀerences
were observed in the CA3 area (113.5¡5.1%) while an
increase was found in CA1 (172.6¡19.9%, p<0.01)
and DG (152.8¡11.6%, p<0.01) (Fig. 4c, d, f). When
BDNF protein level was analysed by Western blot in
the hippocampal total cell lysate after 3 d treatment, a
clear tendency towards increase in the expression of
mature BDNF was observed, although it did not reach
statistical signiﬁcance (140.2¡18.9%; Fig. 4g, h). One
week was required to obtain a signiﬁcant increase in
BDNF protein levels (147¡13%, p<0.05 ; Fig. 4g, h). In
contrast, 7-d oral administration of ﬂuoxetine did not
signiﬁcantly modify BDNF mRNA expression in the
hippocampus (see Supplementary Fig. S2, online).
Hippocampal AKT and CREB expression
Immunoblot analysis of the expression of AKT/PKB
in hippocampal homogenates showed a tendency to
increase after 3 d treatment with the 5-HT4 receptor
agonist with respect to vehicle rats (129.9¡12.2%;
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Fig. 5a, b) ; however, 7 d treatment was necessary to
reach statistical signiﬁcance (140¡14%; Fig. 5a, b).
Moreover, 3-d RS67333 treatment did not signiﬁcantly
modify the hippocampal expression levels of CREB
(115.7¡23.6%; Fig. 5a, b) and its phosphorylated form
(151.4¡32.5%; Fig. 5a, b) in spite of the tendency to
increase. When the treatment was prolonged to 7 d,
the expression of CREB (140¡16%, p<0.05 ;
Fig. 5a, b>) and its phosphorylated form (183¡38%,
p<0.05 ; Fig. 5a, b) were raised to statistically signiﬁ-
cant levels. Interestingly, a signiﬁcant increase of the
pCREB/CREB ratio (193.4¡33.5%, p<0.05 ; Fig. 5a, b)
was seen following 3 d treatment. This increase was
maintained following 7 d treatment (184¡21%,
p<0.05 ; Fig. 5a, b).
Desensibilization of 5-HT4 receptor-mediated
accumulation of cAMP
Incubation of hippocampal membranes with the
5-HT4 agonist zacopride resulted in a concentration-
dependent increase of cAMP for the vehicle and 3-d
treatment experimental groups, while no modiﬁcation
of cAMP accumulation was observed following 7 d
treatment, where cAMP levels were even below the
basal values, although without reaching statistical
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signiﬁcance. There were signiﬁcant diﬀerences be-
tween vehicle and RS67333 (7 d) treated groups with
respect to Emax values (eﬃcacy) (p<0.01) (135.1¡
12.9% vs. 84.1¡2.4%, respectively), but not between
vehicle and RS67333 (3 d) groups (153.0¡19.7%
vs. 135.5¡4.4%, respectively) (Fig. 6). The EC50 values
(potency) were not modiﬁed in any of the diﬀerent
experimental groups (70.9¡49.5 mM vs. 20.8¡13.9 mM,
vehicle and 3-d RS67333 ; and 16.7¡8.5 mM vs.
6.8¡5.2 mM, vehicle and 7-d RS67333 ; Fig. 6). No sig-
niﬁcant changes were observed either in potency and
eﬃcacy of zacopride-induced cAMP accumulation
between 3-d and 7-d vehicles.
Discussion
This work reports the modiﬁcations induced by the
short-term administration (3 d and 7 d) of the 5-HT4
receptor partial agonist, RS67333, on behavioural
paradigms as indicators of antidepressant chronic ef-
ﬁcacy, and several markers of hippocampal neuro-
plasticity previously reported to be modiﬁed by
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chronic administration of antidepressants. Regarding
our results from behavioural paradigms, RS67333 was
eﬀective in the FST following 3 d administration, in
line with previously reported results after acute ad-
ministration (Lucas et al. 2007). Since a single admin-
istration of most antidepressants has been shown to
induce a positive response in this paradigm, the FST is
mostly considered as predictive of antidepressant ef-
ﬁcacy (Cryan et al. 2005). Thus, we undertook another
well-validated paradigm to evaluate antidepressant-
like eﬀects of drugs, the sucrose preference test, in
which corticosterone-treated rats exhibit a decreased
preference and consumption of sucrose that reﬂects an
anhedonic behaviour, a pathognomonic feature of de-
pression states (Gourley & Taylor, 2009). In our study,
this anhedonic state was partially attenuated after 3-d
RS67333 treatment, although 7 d were required to ob-
serve a complete reversion, similar to that induced by
21-d ﬂuoxetine administration. It should be noted that
subchronic ﬂuoxetine is not able to reverse sucrose
intake in this behavioural paradigm (Gourley et al.
2008a, b). The behavioural eﬀect of RS67333 was also
conﬁrmed in the NSF, a test providing an anxiety-
related measure that is sensitive to the eﬀects of
chronic, but not acute or subchronic antidepressant
treatment, as demonstrated with most antidepressants
currently available (Dulawa & Hen, 2005). In our case,
RS67333 showed a tendency to reduce the latency to
feed in NSF after 3 d treatment but 7 d were required
to obtain a statistically signiﬁcant eﬀect in this test. In
contrast, ﬂuoxetine was only eﬀective in this test when
the administration was prolonged up to 28 d, as pre-
viously described (Marcussen et al. 2008). It is note-
worthy that, in the pioneer study (Lucas et al. 2007),
the administration of RS67333 for 3 d resulted in a
partial reversion of the behavioural changes induced
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Fig. 4. Eﬀect of RS67333 treatment on BDNF mRNA and protein expression in the rat hippocampus. Representative in-situ
hybridization autoradiograms in animals treated for 3 d with (a) vehicle or (b) RS67333, and treated for 7 d with (c) vehicle or
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by olfactory bulbectomy, an animal model considered
to reveal predictive capacity of chronic antidepressant
response : the complete reversion of depressive-like
phenotype was evident after 14 d treatment. It should
be mentioned that the duration of treatment with
classical antidepressants required for the full reversion
of these behavioural changes varies from 2 to 4 wk
(Rodriguez-Gaztelumendi et al. 2009; Willner et al.
1987). Taken together, our results show for the ﬁrst
time that a short-term (7 d) administration of a puta-
tive antidepressant induces a complete response in
these paradigms.
In addition to behavioural data, several hippo-
campal neuroplastic changes have been related to
antidepressant eﬃcacy. In this regard, adult neuro-
genesis in the DG is increased after chronic but not
acute administration of classical antidepressants
(Malberg et al. 2000; Pilar-Cue´llar et al. unpublished
observations), although there is some controversy
about the relevance of this neurogenic change in the
mediation of behavioural actions of antidepressants
(Bessa et al. 2009; David et al. 2009; Surget et al. 2008).
Our study shows that a 3-d regimen with RS67333
increased the number of new cells, in agreement with
other authors (Lucas et al. 2007). Furthermore, the
neurogenic changes induced by 7-d administration of
RS67333 reached the level of increase previously re-
ported for classical antidepressants after 2–3 wk
treatment (Malberg et al. 2000; Warner-Schmidt &
Duman, 2007). These data could suggest a possible
relationship between cell proliferation in the adult DG
and antidepressant response. Moreover, they also
demonstrate for the ﬁrst time that this increase is ac-
companied by the accumulation of b-catenin in ANPs
promoting their diﬀerentiation to immature neuro-
blasts. Therefore, it can be suggested that the early
mitogenesis induced by 3 d treatment with the 5-HT4
partial agonist RS67333 is targeting the same type of
cells as ﬂuoxetine to generate new neurons (Encinas
et al. 2006) and is modulating the canonical Wnt path-
way, also targeted by chronic antidepressant therapies
(Madsen et al. 2003; Mostany et al. 2008). It is of note
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that the new cells generated after 3–7 d treatment with
RS67333 would be still immature neuroblasts, as
neural progenitors need at least 28 d to becomemature
(Encinas et al. 2006). Thus, it cannot be fully dis-
counted that immature neuroblasts might play a role
in antidepressant-like responses. These results also
raise the question of whether the induction of adult
neurogenesis by antidepressants is a requirement for
the behavioural eﬀects or just a good correlate of anti-
depressant eﬃcacy. It has been suggested that both
neurogenesis-dependent and -independent mech-
anisms contribute to the antidepressant response
(David et al. 2009). However, our experimental design
did not allow the clariﬁcation of this issue in animals
treated with RS67333 : because of the short duration of
treatment, it was not be possible to study the inte-
gration of the new cells in the existing neuronal net-
works or to analyse their dendritic morphology.
Taking into account that currently used anti-
depressants induce hippocampal CREB and pCREB
expression after chronic but not acute treatment
(Nibuya et al. 1996; Thome et al. 2000), the increase
observed in CREB and pCREB expression after
RS67333 supports the view that short-term treatment
could result in a fully antidepressant response. In a
similar manner, 1 wk of treatment is enough to obtain
signiﬁcant modiﬁcations on the expression of AKT. On
the other hand, 3-d RS67333 administration raised
b-catenin accumulation in neural progenitors, in
addition to increased expression in the whole hippo-
campal fraction. Since the activation of Wnt/b-catenin
signalling pathway is associated with activity-related
neural plasticity and remodelling (Peng et al. 2009;
Yu & Malenka, 2003) and its up-regulation has been
reported after chronic antidepressant (Mostany et al.
2008) and electroconvulsive seizure (ECS) treatments
(Madsen et al. 2003), our results strongly support the
relevance of this neural pathway in the mediation
of the molecular actions of antidepressants. In general
terms, in line with our results from neuroproliferative
studies, a short-term treatment (3–7 d) with RS67333
reaches the level of up-regulation of these signal-
ling pathways previously found following chronic
(2–3 wk) administration of clinically used anti-
depressants.
Several studies have shown that antidepress-
ants up-regulate hippocampal BDNF (Duman &
Monteggia, 2006), although the temporal pattern of
these changes is a matter of debate. While some
authors have reported an induction of BDNF ex-
pression after subchronic treatment (Larsen et al. 2008;
Musazzi et al. 2009), other studies only show up-
regulation of BDNF after chronic antidepressant
administration (De Foubert et al. 2004; Nibuya et al.
1995). Here we report a tendency to increase in ex-
pression of BDNF after 3 d treatment, and a signiﬁcant
increase in the expression of BDNF protein in whole
hippocampal homogenates following a 7-d regimen.
In this regard, an increase in the expression of BDNF
following acute administration of another 5-HT4
agonist (SL65.0155) has been recently reported
(Tamburella et al. 2009). Diﬀerences in the pharmaco-
dynamic and/or kinetic properties might account for
this apparent discrepancy. Previous studies suggest
that the presence of BDNF in the DG is necessary for
the behavioural eﬀects of commonly prescribed anti-
depressants (Adachi et al. 2008) ; in a similar way, in-
fusion of BDNF speciﬁcally into DG, but not CA1,
induces antidepressant-like eﬀects in the FST and
learned helplessness test (Shirayama et al. 2002). Taken
together, these data emphasize the relevance of BDNF
expression in the DG for antidepressant responses. In
this regard, our in-situ hybridization studies revealed
no signiﬁcant changes in BDNF mRNA levels either in
DG or the CA1 ﬁeld after 3-d RS67333 administration,
while 7 d treatment appears to be necessary to increase
BDNF mRNA in DG and CA1. It is of note that, in our
hands, oral administration of ﬂuoxetine for 3 d or 7 d
did not signiﬁcantly modify BDNF mRNA expression
in DG (see Supplementary Fig. S2, online).
The second-messenger cAMP has also been strongly
suggested to be involved in the mechanism of action
of antidepressants (Donati & Rasenick, 2003). In-
terestingly, a signiﬁcant decrease in 5-HT4 receptor-
dependent cAMP production has been reported after
chronic treatment (3 wk) with ﬂuoxetine (Vidal et al.
2009), venlafaxine (Vidal et al. 2010) or imipramine
(Reierson et al. 2009), probably reﬂecting a desensi-
tization process, due to a less eﬃcient coupling to
Gs proteins (Watts, 2002). In this regard, a decreased
aﬃnity of Gs proteins for guanine nucleotides (Manji
et al. 1991), as well as a decrease in Gas protein levels
has been reported after antidepressant treatments
(Lesch et al. 1991, 1992 ; McGowan et al. 1996). We did
not ﬁnd any signiﬁcant diﬀerence in the maximal eﬃ-
cacy or potency of zacopride to increase cAMP levels
after 3-d RS67333 administration, while the 7-d treat-
ment signiﬁcantly reduced zacopride-induced cAMP
accumulation. The reduction in cAMP accumulation
in this experimental group went below basal levels,
although this diﬀerence did not reach statistical sig-
niﬁcance. Our results show that short-term adminis-
tration (7 d) of RS67333 is required to fully desensitize
the post-receptor signalling pathway associated to
5-HT4 receptors, in agreementwith the results obtained
in behavioural tests predictive of chronic response.
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In conclusion, our data show that, after 3 d admin-
istration, the 5-HT4 receptor partial agonist RS67333
shows antidepressant-like positive responses in some
behavioural tests, increases hippocampal cell prolifer-
ation in DG and up-regulates some neuroplasticity-
related markers. Administration for 7 d results in a
complete antidepressant response in those behav-
ioural tests indicative of chronic eﬃcacy, a more
marked increase in the expression of neuroplasticity-
related proteins and a 5-HT4 receptor desensitization,
in line with the modiﬁcations induced by clinically
used antidepressants. It is noteworthy that this is the
ﬁrst study in which the administration of a putative
antidepressant for 3 d and 7 d induces behavioural
and neuroplastic changes in a magnitude fully com-
parable to that previously reported for chronic
(2–3 wk) classical antidepressants. Although caution
is needed when extrapolating results from animals to
humans, our data allow predicting that activation of
5-HT4 receptors provides an encouraging pharmaco-
logical strategy to obtain an early antidepressant
response.
Note
Supplementary material accompanies this paper on
the Journal’s website (http://journals.cambridge.org/
pnp).
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